You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
藥明巨諾-B(02126.HK)獲2seventy bio(TSVT.US)細胞治療產品大中華開發權
藥明巨諾-B(02126.HK)公布,公司與2seventy bio(TSVT.US)建立戰略聯盟,在大中華開發及商業化用於腫瘤適應症的針對MAGE-A4(包括與MAGE-A4結合的工程TCR的任何突變、片段、變型或衍生物)的細胞治療產品,且有可能擴大合作,納入其他項目及其他產品。 據此,2seventy bio有條件授予公司及其聯屬由2seventy bio控制的若干專利及專有技術的權利和許可,以便公司及其聯屬在大中華開發、生產及商業化產品;公司向2seventy bio支付預付款300萬美元及若干里程碑付款及支付特許權使用費,總額將不逾7,000萬美元;及公司將全權負責並承擔在大中華開發及商業化而生產及供應產品的所有成本及開支。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account